Accordingly, CD8+ CTLs have been shown to associate with better survival of colorectal [15], [16], lung [17], [18], oesophageal [19], [20], epithelial ovarian [21], [22], renal cell [23] and pancreatic cancers [24]. Here, CD8A is linked to familial pancreatic carcinoma.